ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

CCOP Reponses So Far Indicates application To Total 150-200

August 27, 1982

In Brief: Appelbaum Clinical Dib. At Hutchinson; Vogelstein Win Pezcoller Award; Curiel To UAB

July 23, 1993

T-Cell Vaccines Cut Time To Protective Immunity

November 25, 2005

Michael Atkins Named Deputy Director at Georgetown Lombardi Cancer Center

March 2, 2012

Also Kevin Cullen named director, Univ. of Maryland Greenebaum Cancer Center.

November 28, 2003

ASCO Strategic Plan Seeks To Increase Value to Members, Public

May 24, 2002